AR076016A1 - Domperidona a una dosis diaria baja para su uso en el tratamiento o la prevencion de una enfermedad asociada a una alteracion de la respuesta inmunitaria - Google Patents
Domperidona a una dosis diaria baja para su uso en el tratamiento o la prevencion de una enfermedad asociada a una alteracion de la respuesta inmunitariaInfo
- Publication number
- AR076016A1 AR076016A1 ARP100101061A ARP100101061A AR076016A1 AR 076016 A1 AR076016 A1 AR 076016A1 AR P100101061 A ARP100101061 A AR P100101061A AR P100101061 A ARP100101061 A AR P100101061A AR 076016 A1 AR076016 A1 AR 076016A1
- Authority
- AR
- Argentina
- Prior art keywords
- domperidone
- alteration
- prevention
- composition according
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/52—Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper and including single- and multilayer analytical elements
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Reivindicacion 1: Composicion que comprende domperidona o una sal farmacéuticamente aceptable de la misma para su uso en el tratamiento o la prevencion en un mamífero de una enfermedad asociada a una alteracion de la respuesta inmunitaria, donde la composicion se prepara para la administracion de una dosis diaria de domperidona de desde 0,2 mg/kg/día hasta 1 mg/kg/día. Reivindicacion 5: Composicion segun cualquier reivindicacion anterior, caracterizada porque se prepara como una forma de dosificacion oral para su administracion una vez al día. Reivindicacion 6: Composicion segun cualquier reivindicacion anterior, caracterizada porque es para su uso en el tratamiento o prevencion en un perro de una enfermedad asociada con una alteracion de la respuesta inmunitaria. Reivindicacion 8: Composicion segun cualquier reivindicacion anterior, caracterizada porque es para su uso en el tratamiento o prevencion de una enfermedad seleccionada del grupo de enfermedades asociadas a una alteracion en la inmunidad celular mediada por linfocitos CD4+Th1. Reivindicacion 9: Composicion segun la reivindicacion 8, caracterizada porque la enfermedad es leishmaniosis. Reivindicacion 15: Composicion segun la reivindicacion 14, caracterizada porque comprende tanto domperidona como un agente leishmanicida tal como antimoniato de N-metilglucamina o miltefosina o bien en una unica forma de dosificacion o bien en formas de dosificacion separadas. Reivindicacion 17: Composicion segun la reivindicacion 16, caracterizada porque comprende tanto domperidona como un agente leishmaniostático tal como alopurinol o bien en una unica forma de dosificacion o bien en formas de dosificacion separadas.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09382040A EP2241317A1 (en) | 2009-03-31 | 2009-03-31 | Domperidone at a low daily dose for use in the treatment or prevention of a disease associated with an alteration of the immune response |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR076016A1 true AR076016A1 (es) | 2011-05-11 |
Family
ID=40801995
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100101061A AR076016A1 (es) | 2009-03-31 | 2010-03-31 | Domperidona a una dosis diaria baja para su uso en el tratamiento o la prevencion de una enfermedad asociada a una alteracion de la respuesta inmunitaria |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US8802691B2 (es) |
| EP (2) | EP2241317A1 (es) |
| AR (1) | AR076016A1 (es) |
| DK (1) | DK2413934T3 (es) |
| ES (2) | ES2559762T3 (es) |
| HU (1) | HUE027348T2 (es) |
| PL (1) | PL2413934T3 (es) |
| PT (1) | PT2413934E (es) |
| WO (1) | WO2010112497A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3949965A1 (en) * | 2020-08-07 | 2022-02-09 | Consejo Superior de Investigaciones Cientificas | Domperidone for use as antiviral agent |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5372818A (en) * | 1993-02-01 | 1994-12-13 | Clemson University | Method of treating fescue toxicosis with domperidone |
| US6224895B1 (en) | 1996-12-18 | 2001-05-01 | Clemson University | Method for promoting ovulation, parturition, and lactation in mammals |
| US7887817B2 (en) * | 2002-01-25 | 2011-02-15 | Aeterna Zentaris Gmbh | Process for preventing protozoal diseases |
| ES2246142B1 (es) | 2004-06-03 | 2007-03-16 | Consejo Sup. Investig. Cientificas | Nueva composicion terapeutica inmunomoduladora. |
-
2009
- 2009-03-31 EP EP09382040A patent/EP2241317A1/en not_active Withdrawn
-
2010
- 2010-03-30 US US13/260,156 patent/US8802691B2/en active Active
- 2010-03-30 PT PT107114050T patent/PT2413934E/pt unknown
- 2010-03-30 WO PCT/EP2010/054177 patent/WO2010112497A1/en active Application Filing
- 2010-03-30 HU HUE10711405A patent/HUE027348T2/en unknown
- 2010-03-30 PL PL10711405T patent/PL2413934T3/pl unknown
- 2010-03-30 EP EP10711405.0A patent/EP2413934B1/en active Active
- 2010-03-30 ES ES10711405.0T patent/ES2559762T3/es active Active
- 2010-03-30 DK DK10711405.0T patent/DK2413934T3/en active
- 2010-03-30 ES ES201190062A patent/ES2397193B1/es not_active Expired - Fee Related
- 2010-03-31 AR ARP100101061A patent/AR076016A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2010112497A1 (en) | 2010-10-07 |
| PL2413934T3 (pl) | 2016-05-31 |
| EP2413934B1 (en) | 2015-10-21 |
| ES2559762T3 (es) | 2016-02-15 |
| ES2397193B1 (es) | 2013-11-26 |
| HUE027348T2 (en) | 2016-10-28 |
| DK2413934T3 (en) | 2016-01-25 |
| EP2241317A1 (en) | 2010-10-20 |
| EP2413934A1 (en) | 2012-02-08 |
| PT2413934E (pt) | 2016-01-25 |
| ES2397193R1 (es) | 2013-03-25 |
| ES2397193A2 (es) | 2013-03-05 |
| US20120065167A1 (en) | 2012-03-15 |
| US8802691B2 (en) | 2014-08-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY35624A (es) | Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington | |
| HRP20220902T3 (hr) | Pripravci i njihova upotreba u liječenju multiple skleroze | |
| BR112017006957A2 (pt) | formulações farmacêuticas para a liberação por via oral de fármacos do tipo de peptídeo ou proteína | |
| EA201690102A1 (ru) | Фармацевтическая композиция, содержащая диметилфумарат, для введения в низкой суточной дозе | |
| MX2016010213A (es) | Formulaciones farmaceuticas novedosas. | |
| JP2015038135A5 (es) | ||
| JP2010222367A5 (es) | ||
| AR075735A1 (es) | Composiciones farmaceuticas de liberacion inmediata que comprenden oxicodona y naloxona. uso | |
| PE20142319A1 (es) | Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero | |
| JP2017506624A5 (es) | ||
| JP2015532296A5 (es) | ||
| NZ606993A (en) | Combination pharmaceutical composition and methods of treating and preventing the infectious diseases | |
| AR090885A1 (es) | Uso de laquinimod en alta dosis para el tratamiento de la esclerosis multiple | |
| NZ625592A (en) | Compositions and methods for the treatment of hepatic diseases and disorders | |
| NZ587202A (en) | Methods for measuring a patient response upon administration of a drug and compositions thereof | |
| PH12020551911A1 (en) | Use of riluzole oral disintigrating tablets for treating diseases | |
| TN2015000135A1 (en) | Modified release formulations for oprozomib | |
| JP2013516493A5 (es) | ||
| GB2523707A (en) | Novel pharmaceutical formulations and their use in the treatment of periodontal disease | |
| MX2024007642A (es) | Uso de tabletas de desintegracion oral de riluzol para tratar enfermedades. | |
| BR112015019776A2 (pt) | comprimidos de duplo uso oral em composições farmacêuticas de sais de sulfato e métodos de uso dos comprimidos | |
| AR098832A1 (es) | Uso de laquinimod para retrasar la progresión de la enfermedad de huntington | |
| PE20130147A1 (es) | Combinacion farmaceutica de teobromina y un agente antitusivo no opioide | |
| RU2016137926A (ru) | Композиции грапипранта и способы их применения | |
| AR080541A1 (es) | Tratamiento para la endometriosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |